Is Follow Up Of ABO Incompatible Transplanted Recipients Different
Follow-up for ABO-incompatible (ABOi) recipients is more intensive than for ABO-compatible (ABOc) recipients, particularly in the early post-transplant period, due to the need for close immunological monitoring and a higher risk of specific complications.
The key differences in follow-up management include:
- Isoagglutinin Titer Monitoring
The most distinct feature of ABOi follow-up is the frequent measurement of anti-A/B antibody titers.
- Monitoring for Rebound:
Clinicians must monitor for a “rebound” of antibody levels, which is most intense in recipients who had high baseline titers (>1:512). - Trigger for Intervention:
While routine postoperative antibody removal (immunoadsorption or plasmapheresis) is now often withheld to reduce bleeding risks, it is still performed “on-demand” if titers rise above specific thresholds (e.g., >1:8 or >1:32). - Sepsis Vigilance:
Follow-up must account for the fact that infections (such as Gram-negative sepsis or UTI) can trigger a sudden boost in anti-A/B titers, potentially leading to late Antibody-Mediated Rejection (ABMR).
- Immunological Vigilance
ABOi recipients require closer observation for Antibody-Mediated Rejection (ABMR), which is significantly more common in this group (10% vs. 2% in compatible controls).
- Biopsy Policies:
Some centers initially used routine protocol biopsies but have transitioned to biopsies “for cause” (when kidney function deteriorates), because staining for C4d is often positive in ABOi grafts even without active rejection. - Graft Function Expectations:
Clinicians expect slightly different functional markers; ABOi recipients often maintain higher serum creatinine levels at one and three years post-transplant compared to ABOc living donor recipients.
- Infectious Disease Surveillance
Because the desensitization process increases the total immunosuppressive burden, the follow-up focus on infection is much more aggressive.
- Infection-Related Mortality:
Roughly 49% of deaths in ABOi recipients are caused by infection, compared to 13% in compatible controls. - Viral Monitoring:
Higher incidence of BK viremia (14% vs. 8%) and CMV (22% vs. 19%) is observed during follow-up. - Bacterial Risk:
High-titer groups are more likely to experience bacterial infections, requiring specialized follow-up to manage multidrug-resistant bacteria.
- Surgical and Hematological Recovery
In the immediate postoperative weeks, follow-up must address the increased bleeding risk.
- Platelet Dysfunction:
ABOi patients “ooze easily” because preoperative immunoadsorption causes platelet depletion and dysfunction. - Transfusion Needs:
They require red blood cell transfusions more than twice as frequently as compatible controls (29% vs. 12%).
- Maintenance Therapy Comparison
Once the initial high-risk period passes (roughly 180 days), maintenance therapy for both groups often converges to standard triple therapy (tacrolimus, MMF, and steroids). Some protocols successfully allow for steroid withdrawal after three months in both ABOi and ABOc groups.
